HONG KONG – South Korean startup Rznomics Inc. has recently secured ₩12 billion (US$10 million) in a series A investment. The Gwangju-based company focuses on cancer treatment development based on RNA platform technology.
BEIJING – Hightide Therapeutics Inc., of Shenzhen, China, and Rockville, Md., said it finished the enrollment in phase IIa trials for its lead asset, HTD-1801, which is a potential first-in-class new molecular entity for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
Allievex Corp., a new company advancing an enzyme replacement therapy for Sanfilippo syndrome type B licensed from Biomarin Pharmaceutical Inc. through a registrational phase II trial, has marked the first close of a series A financing co-led by Novo Holdings and the startup's founder, Pappas Capital.
BEIJING – Hightide Therapeutics Inc., of Shenzhen, China, and Rockville, Md., said it finished the enrollment in phase IIa trials for its lead asset, HTD-1801, which is a potential first-in-class new molecular entity for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
HONG KONG – South Korea's biopharmaceutical venture Genome & Co. Ltd. recently secured KRW30.2 billion (US$25.2 million) in series C investment with an IPO and global clinical trial plans for next year.
It took newly launched Plexium Inc. CEO Kandaswamy (Swamy) Vijayan a few years to figure out where he needed to focus his creative energies. With an engineering background, he helped develop diagnostic tools. But he wanted to take the skill further.
TORONTO – Developed by Edmonton, Alberta-based Itraumacare Inc., the Itclamp has undergone multiple independent and peer-reviewed studies demonstrating its efficacy controlling blood flow from wounds to the head and neck during military combat in the Middle East. That's been enough for the U.S. Department of Defense's Committee on Tactical Combat Casualty Care to officially recommend its acquisition for use on battlefields.
Magnetic resonance imaging (MRI) machines typically require a dedicated shielded room, as well as an additional room with electronics for analytics. That makes MRI, with a typical costly system that requires whole body immersion and elaborate facilities, not particularly feasible for many health care settings.
Palo Alto, Calif.-based startup Doc.ai is training its sights on the $9.5 billion global epilepsy market, with the aim of using artificial intelligence to help patients find the best medication to control their seizures. To that end, the company is teaming up with the Stanford University School of Medicine and the Stanford Epilepsy Center on a digital health trial to develop a predictive treatment model that will identify the right treatment at the right time for individuals living with epilepsy.
"Microbiome" has become a health and wellness buzzword, implicated as a contributing factor in conditions ranging from diabetes and obesity to gastrointestinal disease, autoimmune diseases and even autism. But the tools scientists use to cultivate bacteria have changed little over the past century, said Peter Christey, founder and CEO of San Carlos, Calif.-based startup General Automation Lab Technologies Inc. (GALT).
RSS
